Efficacy of Zenocutuzumab in <i>NRG1</i> Fusion–Positive Cancer

Zenocutuzumab showed efficacy in patients with advanced <i>NRG1</i> fusion-positive cancer, notably NSCLC and pancreatic cancer, with mainly low-grade adverse events. (Funded by Merus; eNRGy ClinicalTrials.gov number, NCT02912949.).

Authors

Institutions

Publication Details

Journal
New England Journal of Medicine
Published
2025-02-05
DOI
https://doi.org/10.1056/nejmoa2405008
Citations
91
Primary Topic
Neuroendocrine Tumor Research Advances
Type
article
Field-Weighted Citation Impact
123.23
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Efficacy of Zenocutuzumab in NRG1 Fusion–Positive Cancer

Kim A. Reiss, Jim Ford, Cindy Neuzillet, Frans L. Opdam et al.
91 citations
New England Journal of Medicine
Neuroendocrine Tumor Research Advances
123.23
article

Efficacy of Zenocutuzumab in NRG1 Fusion–Positive Cancer

Kim A. Reiss, Jim Ford, Cindy Neuzillet, Frans L. Opdam, Christoph Springfeld, Grainne M. O’Kane, James M. Cleary, Sun Young Rha, Jordi Rodón, Lokesh Jain, Kazumi Nishino, Kōichi Goto, Ernesto Wasserman, M. Duruisseaux, Stephen V. Liu, Shola Adeyemi, Viktoriya Stalbovskaya, Emiliano Calvo, Benjamin A. Weinberg, Misako Nagasaka, Kumiko Umemoto, Alexander Edward Dela Cruz Drilon, Tanios Bekaii‐Saab, Eileen Mary O'Reilly, Teresa Macarulla, Shekeab Jauhari, Antoine Hollebecque, Sai‐Hong Ignatius Ou, Alison M. Schram, Joon Oh Park, Dong-Wan Kim, Andrew K. Joe
article en
91 citations

Abstract

Zenocutuzumab showed efficacy in patients with advanced <i>NRG1</i> fusion-positive cancer, notably NSCLC and pancreatic cancer, with mainly low-grade adverse events. (Funded by Merus; eNRGy ClinicalTrials.gov number, NCT02912949.).

New England Journal of MedicineVol. 392(6)
Université Claude Bernard Lyon 1 (FR), Hebron University (PS), Memorial Sloan Kettering Cancer Center (US), The University of Texas MD Anderson Cancer Center (US), Harvard University (US), Inserm (FR), St. Marianna University School of Medicine (JP), Georgetown University (US), University of California, Irvine (US), Cornell University (US), Heidelberg University (DE), Georgetown University Medical Center (US), Institut Gustave Roussy (FR), University Hospital Heidelberg (DE), Samsung Medical Center (KR), Princess Margaret Cancer Centre (CA), Seoul National University Hospital (KR), The Netherlands Cancer Institute (NL), Hospices Civils de Lyon (FR), National Center for Tumor Diseases (DE), Dana-Farber Cancer Institute (US), South Texas Accelerated Research Therapeutics (US), Centre de Recherche en Cancérologie de Lyon (FR), Mayo Clinic Hospital (US), Merus (Netherlands) (NL), Hôpital Louis Pradel (FR), National Cancer Center Hospital East (JP), Osaka International Cancer Institute (JP), Yonsei University Health System (KR), Vall d'Hebron Institute of Oncology (ES), University of Pennsylvania (US), Sungkyunkwan University (KR)
Zero hunger
Openalex Percentile: Top 0%
Neuroendocrine Tumor Research Advances
123.23
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.